Deutsche Märkte öffnen in 28 Minuten

Abiomed, Inc. (ABMD)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
244,40+1,91 (+0,79%)
Börsenschluss: 04:00PM EDT
244,40 0,00 (0,00%)
Nachbörse: 04:11PM EDT

Abiomed, Inc.

22 Cherry Hill Drive
Danvers, MA 01923
United States
978 646 1400
https://www.abiomed.com

Sektor(en)Healthcare
BrancheMedical Devices
Vollzeitmitarbeiter2.003

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Michael R. MinogueChairman, CEO & Pres3,04M26,95M1967
Mr. Todd A. TrappExec. VP & CFO914,93kN/A1971
Mr. Marc A. BeganExec. VP, Gen. Counsel & Sec.818,64kN/A1967
Mr. Andrew J. GreenfieldExec. VP & Chief Commercial Officer804,95kN/A1973
Dr. David M. Weber Ph.D.Scientific & Technology Advisor1,02M6,79M1961
Mr. Matthew T. PlanoExec. VP of Global Operations & IntegrationN/AN/A1965
Dr. Thorsten Siess Ph.D.VP & CTON/AN/AN/A
Ms. Ingrid Goldberg WardDirector of Investor RelationsN/AN/AN/A
Sarah KarrCommunications Mang.N/AN/AN/A
Mr. Michael G. HowleyVP & GM of Global SalesN/AN/A1964
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Corporate Governance

Abiomed, Inc.s ISS Governance QualityScore, Stand 1. Juli 2022, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 9, Shareholderrechte: 10, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.